Abstract
1. Dawson LA, Normolle D, Balter JM, et al. Analysis of radiationinduced liver disease using the Lyman NTCP model. Int J RadiatOncol Biol Phys 2002;53:810-821. 2. Dawson LA, Eccles C, Craig T. Individualized image guided iso-NTCP based liver cancer SBRT. Acta Oncol. 2006; 45:856–864. 3. Cardenes HR, Price TR, Perkins SM, et al. Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. Clin Transl Oncol 2010;12:218-225. 4. Tse RV, Hawkins M, Lockwood G, et al. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 2008;26:657-664. 5. Zeng ZC, Tang ZY, Fan J, et al. A comparison of chemoembolization combination with and without radiotherapy for unresectable hepatocellular carcinoma. Cancer J 2004;10:307-316. The specific aims were to: 1) evaluate the safety and effectiveness of SBRT for primary liver HCC as adjuvant therapy following resection and/or catheter based therapy in pts with Child-Pugh A-C (BCLC A-D) and 2) to evaluate the outcomes of patients who underwent liver transplantation following SBRT. References •SBRT, either in combination with arterially directed therapy or as a single modality treatment for HCC resulted in encouraging survival, even in patients with more advanced baseline liver disease (CTP C/BCLC D) and patients who had multiple prior liver directed therapies (TACE, RFA, resection).
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
